Sudan virus disease outbreak in Uganda: urgent research gaps
The Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/7/12/e010982.full |
| _version_ | 1797784222025383936 |
|---|---|
| author | Duduzile Edith Ndwandwe Alice Norton Susan Khader Ibrahim Katherina Thomas |
| author_facet | Duduzile Edith Ndwandwe Alice Norton Susan Khader Ibrahim Katherina Thomas |
| author_sort | Duduzile Edith Ndwandwe |
| collection | DOAJ |
| description | The Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued to spread to several regions including the capital. The ongoing transmission, uncertain case numbers and no licensed vaccine or therapeutics available are a cause for concern. We searched four databases for SUDV research using the search terms “SUDV”, “Sudan Virus” and “Ebola Sudan”. Our analysis identified only 20 SUDV research studies. Most were implemented in the USA and only one in Uganda. Nine studies were on therapeutics, eight on vaccines, one on diagnostics, one in one health and one in social science. Our data highlight a lack of SUDV research and an urgent need for investment to identify an effective vaccine, and optimal supportive care and therapeutic strategies for all at risk groups as a key research priority. Research investments should be prioritised into vaccines and treatment strategies that will be accessible to high-risk populations in affected regions during the outbreak, to protect populations, improve individual outcomes and facilitate outbreak control. |
| first_indexed | 2024-03-13T00:36:49Z |
| format | Article |
| id | doaj.art-78c739b2926e4b32a48487fe9fa2e9c5 |
| institution | Directory Open Access Journal |
| issn | 2059-7908 |
| language | English |
| last_indexed | 2024-03-13T00:36:49Z |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Global Health |
| spelling | doaj.art-78c739b2926e4b32a48487fe9fa2e9c52023-07-09T21:00:07ZengBMJ Publishing GroupBMJ Global Health2059-79082022-12-0171210.1136/bmjgh-2022-010982Sudan virus disease outbreak in Uganda: urgent research gapsDuduzile Edith Ndwandwe0Alice Norton1Susan Khader Ibrahim2Katherina Thomas3Cochrane South Africa, South African Medical Research Council, Cape Town, Western Cape, South AfricaUK Collaborative on Development Research, London, UKGloPID-R Research and Policy Team, Pandemic Sciences Institute, University of Oxford, Oxford, UKWalimu, NGO, Kampala, UgandaThe Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued to spread to several regions including the capital. The ongoing transmission, uncertain case numbers and no licensed vaccine or therapeutics available are a cause for concern. We searched four databases for SUDV research using the search terms “SUDV”, “Sudan Virus” and “Ebola Sudan”. Our analysis identified only 20 SUDV research studies. Most were implemented in the USA and only one in Uganda. Nine studies were on therapeutics, eight on vaccines, one on diagnostics, one in one health and one in social science. Our data highlight a lack of SUDV research and an urgent need for investment to identify an effective vaccine, and optimal supportive care and therapeutic strategies for all at risk groups as a key research priority. Research investments should be prioritised into vaccines and treatment strategies that will be accessible to high-risk populations in affected regions during the outbreak, to protect populations, improve individual outcomes and facilitate outbreak control.https://gh.bmj.com/content/7/12/e010982.full |
| spellingShingle | Duduzile Edith Ndwandwe Alice Norton Susan Khader Ibrahim Katherina Thomas Sudan virus disease outbreak in Uganda: urgent research gaps BMJ Global Health |
| title | Sudan virus disease outbreak in Uganda: urgent research gaps |
| title_full | Sudan virus disease outbreak in Uganda: urgent research gaps |
| title_fullStr | Sudan virus disease outbreak in Uganda: urgent research gaps |
| title_full_unstemmed | Sudan virus disease outbreak in Uganda: urgent research gaps |
| title_short | Sudan virus disease outbreak in Uganda: urgent research gaps |
| title_sort | sudan virus disease outbreak in uganda urgent research gaps |
| url | https://gh.bmj.com/content/7/12/e010982.full |
| work_keys_str_mv | AT duduzileedithndwandwe sudanvirusdiseaseoutbreakinugandaurgentresearchgaps AT alicenorton sudanvirusdiseaseoutbreakinugandaurgentresearchgaps AT susankhaderibrahim sudanvirusdiseaseoutbreakinugandaurgentresearchgaps AT katherinathomas sudanvirusdiseaseoutbreakinugandaurgentresearchgaps |